{"id":11293,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T15:51:00","modified_gmt":"2025-10-03T15:51:00","slug":"hypertermie-preziti-pacientu","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/cs\/hypertermie-preziti-pacientu\/","title":{"rendered":"Hypertermie a P\u0159e\u017eit\u00ed u Onkologick\u00fdch Pacient\u016f: Klinick\u00e9 D\u016fkazy Ukazuj\u00ed Zv\u00fd\u0161en\u00ed Celkov\u00e9ho P\u0159e\u017eit\u00ed (OS) o V\u00edce Ne\u017e 50 %"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hypertermie a P\u0159e\u017eit\u00ed u Onkologick\u00fdch Pacient\u016f: Klinick\u00e9 D\u016fkazy Ukazuj\u00ed Zv\u00fd\u0161en\u00ed Celkov\u00e9ho P\u0159e\u017eit\u00ed (OS) o V\u00edce Ne\u017e 50 %\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hypertermie, Onkologie, Studie F\u00e1ze III, p\u0159e\u017eit\u00ed, OS, Kompletn\u00ed Odpov\u011b\u010f, CR, Glioblastom, rakovina slinivky, Sarkom, rakovina d\u011blo\u017en\u00edho \u010d\u00edpku, rakovina prsu, E-E-A-T\"\n      \/* ... Schema FAQPage by byl p\u0159id\u00e1n samostatn\u011b pro sekci \u010casto Kladen\u00e9 Ot\u00e1zky *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorita a Odbornost (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vyvinuli <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cs\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, a <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cs\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hypertermie a P\u0159e\u017eit\u00ed u Onkologick\u00fdch Pacient\u016f: Klinick\u00e9 D\u016fkazy Ukazuj\u00ed Zv\u00fd\u0161en\u00ed Celkov\u00e9ho P\u0159e\u017eit\u00ed (OS) o V\u00edce Ne\u017e 50 % v Ur\u010dit\u00fdch P\u0159\u00edpadech<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V boji proti rakovin\u011b je kone\u010dn\u00fdm c\u00edlem prodlou\u017eit <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Celkov\u00e9 P\u0159e\u017eit\u00ed (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">s minim\u00e1ln\u00ed nebo \u017e\u00e1dnou dodate\u010dnou toxicitou<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> D\u00edky sv\u00e9 jedine\u010dn\u00e9 schopnosti senzibilizovat n\u00e1dorov\u00e9 bu\u0148ky na radioterapii a chemoterapii, <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hypertermie (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> tento c\u00edl p\u0159ekonala. Data z <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cs\/hypertermie-studii-faze-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">randomizovan\u00fdch klinick\u00fdch studi\u00ed F\u00e1ze III (RCT) a meta-anal\u00fdz<\/span><\/span><\/strong> <\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ukazuj\u00ed, \u017ee p\u0159id\u00e1n\u00ed Hypertermie ke standardn\u00edm protokol\u016fm m\u016f\u017ee zv\u00fd\u0161it <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*Celkov\u00e9 P\u0159e\u017eit\u00ed o 20 %, 50 %, a dokonce o v\u00edce ne\u017e 100 %<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> u vysoce agresivn\u00edch karcinom\u016f. P\u0159edstavujeme nejp\u0159esv\u011bd\u010div\u011bj\u0161\u00ed d\u016fkazy s p\u0159\u00edm\u00fdmi odkazy na zdrojov\u00e9 publikace:<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Zdvojn\u00e1soben\u00e1 M\u00edra P\u0159e\u017eit\u00ed po 2 Letech: Glioblastom Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Glioblastom Multiforme (GBM) je nejagresivn\u011bj\u0161\u00ed mozkov\u00fd n\u00e1dor <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Randomizovan\u00e1 klinick\u00e1 studie F\u00e1ze I\/II<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] uk\u00e1zala, \u017ee p\u0159id\u00e1n\u00ed Hypertermie k brachiterapii, po konven\u010dn\u00ed radioterapii, m\u011blo dramatick\u00fd dopad na progn\u00f3zu onkologick\u00fdch pacient\u016f, a to * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">zdvojn\u00e1soben\u00edm m\u00edry p\u0159e\u017eit\u00ed po 2 letech<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onkologick\u00fd Ukazatel<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standardn\u00ed L\u00e9\u010dba (Bez HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standardn\u00ed + Hypertermie (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relativn\u00ed \u00da\u010dinek (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u0159e\u017eit\u00ed &#8211; 2 Roky<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">15 %<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">31 %<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relativn\u00ed Zv\u00fd\u0161en\u00ed OS o +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relativn\u00ed zv\u00fd\u0161en\u00ed p\u0159e\u017eit\u00ed u onkologick\u00fdch pacient\u016f po 2 letech o v\u00edce ne\u017e 100 % je p\u0159esv\u011bd\u010div\u00fdm d\u016fkazem \u00fa\u010dinnosti Hypertermie jako adjuvantn\u00ed onkologick\u00e9 l\u00e9\u010dby<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nov\u011bj\u0161\u00ed meta-anal\u00fdzy [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> potvrzuj\u00ed podobn\u00e9 p\u0159\u00ednosy Modulovan\u00e9 RF Hypertermie (mHT) u nov\u011b diagnostikovan\u00e9ho onemocn\u011bn\u00ed, s <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">m\u00edrou p\u0159e\u017eit\u00ed po 1 roce 73% ve srovn\u00e1n\u00ed s 37% v kontroln\u00ed skupin\u011b<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (recidivuj\u00edc\u00ed onemocn\u011bn\u00ed) (p = 0,0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Siln\u00e9 sign\u00e1ly p\u0159e\u017eit\u00ed z komparativn\u00edch studi\u00ed, a to i v n\u00e1ro\u010dn\u00e9m klinick\u00e9m kontextu gliom\u016f, ospravedl\u0148uj\u00ed za\u0159azen\u00ed HT jako indikace \u00darovn\u011b 1A do klinick\u00fdch doporu\u010den\u00ed.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Prodlou\u017een\u00e1 Doba P\u0159e\u017eit\u00ed: Zv\u00fd\u0161en\u00ed OS o V\u00edce Ne\u017e 50 % u Rakoviny Slinivky<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Slinivky B\u0159i\u0161n\u00ed (Pancreatic Carcinoma, PC) m\u00e1 jednu z nejhor\u0161\u00edch progn\u00f3z. Konsolidovan\u00e9 klinick\u00e9 d\u016fkazy ukazuj\u00ed, \u017ee Hypertermie v\u00fdznamn\u011b m\u011bn\u00ed klinick\u00fd pr\u016fb\u011bh, p\u0159i\u010dem\u017e konzistentn\u011b prokazuje zv\u00fd\u0161en\u00ed OS u onkologick\u00fdch pacient\u016f o v\u00edce ne\u017e 50 %:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Adjuvantn\u00ed Randomizovan\u00e1 Klinick\u00e1 Studie HEAT (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* U resekabiln\u00edho dukt\u00e1ln\u00edho adenokarcinomu slinivky vedlo p\u0159id\u00e1n\u00ed Region\u00e1ln\u00ed Hypertermie (RHT) k <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">m\u00edr\u00e1m p\u0159e\u017eit\u00ed po 5 letech 28,4% oproti 18,7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">relativn\u00ed zv\u00fd\u0161en\u00ed p\u0159e\u017eit\u00ed o 52%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Komparativn\u00ed Integrativn\u00ed Studie (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* U metastatick\u00e9 rakoviny slinivky byla integrativn\u00ed imunomodula\u010dn\u00ed l\u00e9\u010dba (v\u010detn\u011b Modulovan\u00e9 RF Hypertermie mHT) v\u00fdrazn\u011b lep\u0161\u00ed ne\u017e konven\u010dn\u00ed chemoterapie.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Rakovina slinivky - celkov\u00e9 p\u0159e\u017eit\u00ed OS - srovn\u00e1n\u00ed mezi imunomodula\u010dn\u00edmi terapiemi (IMT) VS chemoterapi\u00ed (CT) VS Modulovanou RF Hypertermie (mHT) + CT\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">Rakovina slinivky &#8211; celkov\u00e9 p\u0159e\u017eit\u00ed OS &#8211; srovn\u00e1n\u00ed mezi imunomodula\u010dn\u00edmi terapiemi (IMT) VS chemoterapi\u00ed (CT) VS Modulovanou RF Hypertermi\u00ed (mHT) + CT<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Velk\u00e1 retrospektivn\u00ed, multicentrick\u00e1 observa\u010dn\u00ed studie<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 pacient\u016f s PC stadiem III-IV) srovn\u00e1vala Modulovanou RF Hypertermii (mHT) + chemoterapii CT (p\u0159ev\u00e1\u017en\u011b na b\u00e1zi gemcitabinu) s pouze chemoterapi\u00ed CT. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Celkov\u00e9 P\u0159e\u017eit\u00ed (OS): OS bylo v\u00fdznamn\u011b zlep\u0161eno (v\u00edce ne\u017e ZDVOJN\u00c1SOBENO) ve skupin\u011b Modulovan\u00e9 RF Hypertermie (mHT) (20 m\u011bs\u00edc\u016f, oproti 9 m\u011bs\u00edc\u016fm ve skupin\u011b CT, P &lt; 0,001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf P\u0159e\u017eit\u00ed Bez Progrese (PFS): PFS bylo tak\u00e9 v\u00fdznamn\u011b zlep\u0161eno (7 m\u011bs\u00edc\u016f, oproti 5 m\u011bs\u00edc\u016fm, P &lt; 0,05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Odpov\u011b\u010f N\u00e1doru: Pacienti l\u00e9\u010den\u00ed lok\u00e1ln\u00ed RF Hypertermi\u00ed (mHT) m\u011bli v\u00fdznamn\u011b vy\u0161\u0161\u00ed m\u00edru \u010c\u00e1ste\u010dn\u00e9 Odpov\u011bdi (PR) (45% oproti 24%, P = 0,0018) a v\u00fdznamn\u011b ni\u017e\u0161\u00ed M\u00edru Progrese (PD) (4% oproti 31%, P &lt; 0,01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Dlouhodob\u00e1 Dokumentace F\u00e1ze III: Sarkom M\u011bkk\u00fdch Tk\u00e1\u0148 (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V mnohon\u00e1rodn\u00ed randomizovan\u00e9 klinick\u00e9 studii F\u00e1ze III (RCT), zlat\u00e9m standardu,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">u pacient\u016f podstupuj\u00edc\u00edch NACT (neoadjuvantn\u00ed chemoterapii) pro sarkom m\u011bkk\u00fdch tk\u00e1\u0148 (STS), <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">byl medi\u00e1n Celkov\u00e9ho P\u0159e\u017eit\u00ed (OS) v\u00edce ne\u017e ZDVOJN\u00c1SOBEN<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , s minim\u00e1ln\u00ed toxicitou <\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, co\u017e vedlo k za\u0159azen\u00ed HT do doporu\u010den\u00ed NCCN a ESMO.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Studie byla iniciov\u00e1na <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Evropskou Spole\u010dnost\u00ed pro Hypertermickou Onkologii (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> a koordinov\u00e1na Klinikum der Universit\u00e4t M\u00fcnchen, N\u011bmecko, ve spolupr\u00e1ci se Skupinou pro Sarkom M\u011bkk\u00fdch Tk\u00e1\u0148 a Kost\u00ed (STBSG) p\u0159i Evropsk\u00e9 Organizaci pro V\u00fdzkum a L\u00e9\u010dbu Rakoviny (EORTC). Z\u00fa\u010dastn\u011bn\u00e1 akademick\u00e1 centra byla v N\u011bmecku (6), Norsku (1), Rakousku (1) a USA (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dosp\u011bl\u00ed pacienti (v\u011bk \u226518 let) s lokalizovan\u00fdm sarkomem m\u011bkk\u00fdch tk\u00e1\u0148 (n\u00e1dor \u22655 cm, stupe\u0148 2 nebo 3, hlubok\u00fd, dle klasifikace Francouzsk\u00e9 N\u00e1rodn\u00ed Federace Center pro Kontrolu Rakoviny [FNCLCC]) byli za\u0159azeni v 9 centrech od \u010dervence 1997 do listopadu 2006. Sledov\u00e1n\u00ed bylo ukon\u010deno v prosinci 2014. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u0159id\u00e1n\u00ed Region\u00e1ln\u00ed Hypertermie (RHT) prodlou\u017eilo medi\u00e1n p\u0159e\u017eit\u00ed bez onemocn\u011bn\u00ed ze 17,4 m\u011bs\u00edce na 33,3 m\u011bs\u00edce<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR pro lok\u00e1ln\u00ed nebo vzd\u00e1len\u00e9 selh\u00e1n\u00ed nebo \u00famrt\u00ed, 0,71; 95% IS, 0,55\u20130,93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0,01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Obr\u00e1zek 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>P\u0159e\u017eit\u00ed mezi studijn\u00edmi skupinami bylo v\u00fdznamn\u011b zlep\u0161eno ve skupin\u011b NACT plus RHT, s medi\u00e1nem trv\u00e1n\u00ed 15,4 roku ve srovn\u00e1n\u00ed s 6,2 roku ve skupin\u011b pouze NACT<\/strong> (HR 0,73; 95% IS, 0,54-0,98;\u00a0<i>P<\/i>\u2009=\u20090,04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Obr\u00e1zek 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>M\u00edry p\u0159e\u017eit\u00ed po 5 a 10 letech byly 62,7 % (95% IS, 55,2%-70,1%) a 52,6 % (95% IS, 44,7%-60,6%) ve skupin\u011b NACT plus RHT<\/strong> a 51,3 % (95% IS, 43,7%-59,0%) a 42,7 % (95% IS, 35,0%-50,4%) ve skupin\u011b pouze NACT, v tomto po\u0159ad\u00ed. Po\u010det pacient\u016f, kter\u00e9 bylo nutn\u00e9 l\u00e9\u010dit k dosa\u017een\u00ed p\u0159\u00ednosu v p\u0159e\u017eit\u00ed po 5 a 10 letech, byl 8,8 a 10,1, v tomto po\u0159ad\u00ed. Post-hoc anal\u00fdzy uk\u00e1zaly, \u017ee u pacient\u016f s n\u00e1dory kon\u010detin byly m\u00edry p\u0159e\u017eit\u00ed po 5 a 10 letech ve prosp\u011bch RHT 75,2 % oproti 60,8 % (absolutn\u00ed rozd\u00edl, 14,4 %; 95% IS, 0,0%-29,5%) a 68,3 % oproti 59,2 % (absolutn\u00ed rozd\u00edl, 9,1 %; 95% IS, 0%-24,7%). U pacient\u016f s n\u00e1dory, kter\u00e9 nebyly na kon\u010detin\u00e1ch, byly m\u00edry p\u0159e\u017eit\u00ed po 5 a 10 letech ve prosp\u011bch RHT 53,5 % oproti 44 % (absolutn\u00ed rozd\u00edl, 9,5 %; 95% IS, 0%-23,8%) a 41,3 % oproti 29,9 % (absolutn\u00ed rozd\u00edl, 11,4 %; 95% IS 0%-25,1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Obr\u00e1zek 2<\/a>D). Souhrn v\u00fdsledk\u016f l\u00e9\u010dby je uveden v eTabulce 1 v\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Dopl\u0148ku 2<\/a>.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u0159e\u017eit\u00ed bylo v\u00fdznamn\u011b zlep\u0161eno p\u0159id\u00e1n\u00edm region\u00e1ln\u00ed hypertermie k neoadjuvantn\u00ed chemoterapii, s absolutn\u00edm rozd\u00edlem 11,4 % po 5 letech a 9,9 % po 10 letech,<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ve srovn\u00e1n\u00ed se samotnou neoadjuvantn\u00ed chemoterapi\u00ed.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. D\u016fkazy \u00darovn\u011b 1A z Klinick\u00fdch Studi\u00ed F\u00e1ze III: Zlep\u0161en\u00ed Kompletn\u00ed Odpov\u011bdi (CR) a P\u0159e\u017eit\u00ed (OS)<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina D\u011blo\u017en\u00edho \u010c\u00edpku (12let\u00e9 sledov\u00e1n\u00ed)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* Nizozemsk\u00e1 Klinick\u00e1 Studie Hlubok\u00e9 Hypertermie (F\u00e1ze III), aktualizovan\u00e1 po 12 letech sledov\u00e1n\u00ed, uk\u00e1zala velk\u00e9 zlep\u0161en\u00ed v Celkov\u00e9m P\u0159e\u017eit\u00ed (OS): <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% ve skupin\u011b RT+HT oproti 20% ve skupin\u011b pouze RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Recidivuj\u00edc\u00ed Rakovina Prsu (Hrudn\u00ed St\u011bna)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Meta-anal\u00fdza<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> uk\u00e1zala <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">relativn\u00ed zv\u00fd\u0161en\u00ed m\u00edry Kompletn\u00ed Odpov\u011bdi (CR) o +58% p\u0159id\u00e1n\u00edm HT k re-oz\u00e1\u0159en\u00ed. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ve studi\u00edch se 2 rameny bylo <strong>Kompletn\u00ed Odpov\u011bdi (CR) dosa\u017eeno u 60,2 %<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">s RT + HT ve srovn\u00e1n\u00ed s 38,1 % s pouze RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(pom\u011br \u0161anc\u00ed 2,64, 95% interval spolehlivosti [IS] 1,66\u20134,18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001). Pom\u011br rizik a rozd\u00edl rizik byly 1,57 (95% IS 1,25\u20131,96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001) a 0,22 (95% IS 0,11\u20130,33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0,0001), v tomto po\u0159ad\u00ed.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Kone\u010dn\u00edku (Pokro\u010dil\u00e1\/Recidivuj\u00edc\u00ed)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Po 5 letech sledov\u00e1n\u00ed byly m\u00edry Celkov\u00e9ho P\u0159e\u017eit\u00ed (OS) <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95,8 oproti 74,5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,045), P\u0159e\u017eit\u00ed Bez Onemocn\u011bn\u00ed (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89,1 oproti 70,4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,027), P\u0159e\u017eit\u00ed Bez Lok\u00e1ln\u00edho Recidivu ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97,7 oproti 78,7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,006) a P\u0159e\u017eit\u00ed Bez Kolostomie ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87,7 oproti 69,0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,016) v\u00fdznamn\u011b lep\u0161\u00ed pro skupinu onkologick\u00fdch pacient\u016f s Hypertermi\u00ed p\u0159idanou k l\u00e9\u010db\u011b.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Hlavy a Krku (HNC)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomizovan\u00e9 studie F\u00e1ze III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> uk\u00e1zaly <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">konzistentn\u00ed zv\u00fd\u0161en\u00ed 5let\u00e9ho OS z 50% na 68,4% (p &lt; 0,005). 5let\u00e9 P\u0159e\u017eit\u00ed Bez Onemocn\u011bn\u00ed (DFS) se zv\u00fd\u0161ilo z 25,5% na 51,3% (p &lt; 0,005). M\u00edra CR se tak\u00e9 zv\u00fd\u0161ila z 62,8% na 81,6%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . V jin\u00e9 <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">studii F\u00e1ze III[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">byla Kompletn\u00ed Odpov\u011b\u010f (CR) pozorov\u00e1na u 42,4 % ve skupin\u011b pouze radioterapie oproti 78,6 % ve skupin\u011b s HT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Rozd\u00edl byl statisticky v\u00fdznamn\u00fd (&lt; 0,05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vysoce Rizikov\u00fd Malign\u00ed Melanom (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Klinick\u00e1 studie F\u00e1ze II\/III[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> uk\u00e1zala, \u017ee Region\u00e1ln\u00ed Hypertermie v kombinaci s chemoterapi\u00ed v\u00fdznamn\u011b zlep\u0161uje Celkov\u00e9 P\u0159e\u017eit\u00ed i u pacient\u016f s pokro\u010dil\u00fdm melanomem:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5let\u00e9 Celkov\u00e9 P\u0159e\u017eit\u00ed:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Celkov\u00e1 m\u00edra byla 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5let\u00e9 p\u0159e\u017eit\u00ed pro pacienty s kompletn\u011b kontrolovan\u00fdm onemocn\u011bn\u00edm:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Zv\u00fd\u0161ilo se na <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aktu\u00e1rn\u00ed Lok\u00e1ln\u00ed Kontrola po 2 Letech <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% OPROTI <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% ve skupin\u011b s HT <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00fdznamn\u00e9 Zlep\u0161en\u00ed (p = 0,008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Mo\u010dov\u00e9ho M\u011bch\u00fd\u0159e (Ne-svalov\u011b Invazivn\u00ed)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Rakovina mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e je jednou z indikac\u00ed \u00darovn\u011b 1A pro p\u0159id\u00e1n\u00ed Hypertermie k onkologick\u00e9 l\u00e9\u010db\u011b.[12] Hypertermick\u00e1 Intravezik\u00e1ln\u00ed Chemoterapie (HIVEC) v kombinaci s Mitomycinem C je zaveden\u00e1 metoda, kter\u00e1 prokazuje v\u00fdznamn\u00e9 zlep\u0161en\u00ed v m\u00ed\u0159e recidiv:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sn\u00ed\u017een\u00ed Recidivy: U ne-svalov\u011b invazivn\u00ed rakoviny mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e se st\u0159edn\u00edm a vysok\u00fdm rizikem se HIVEC uk\u00e1zal b\u00fdt lep\u0161\u00ed ne\u017e standardn\u00ed instilace chemoterapie p\u0159i pokojov\u00e9 teplot\u011b.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konsolidovan\u00e9 V\u00fdsledky: Meta-anal\u00fdzy a klinick\u00e9 studie (v\u010detn\u011b randomizovan\u00fdch studi\u00ed) hl\u00e1sily sn\u00ed\u017een\u00ed rizika recidivy o v\u00edce ne\u017e 30 % ve srovn\u00e1n\u00ed se standardn\u00ed intravezik\u00e1ln\u00ed chemoterapi\u00ed u pacient\u016f se st\u0159edn\u00edm a vysok\u00fdm rizikem [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00da\u010dinnost p\u0159i Selh\u00e1n\u00ed BCG: HIVEC je d\u016fle\u017eitou alternativou pro pacienty, u kter\u00fdch standardn\u00ed terapie BCG (Bacillus Calmette-Gu\u00e9rin) selhala nebo je kontraindikov\u00e1na, zlep\u0161uj\u00edc\u00ed P\u0159e\u017eit\u00ed Bez Recidivy (RFS).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. Bezpe\u010dnost a P\u0159\u00edzniv\u00fd Terapeutick\u00fd Index (Toxicita)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kl\u00ed\u010dov\u00fdm aspektem dokumentace F\u00e1ze III je, \u017ee obrovsk\u00fd p\u0159\u00ednos v p\u0159e\u017eit\u00ed je dosa\u017een bez v\u00fdznamn\u00e9ho zv\u00fd\u0161en\u00ed z\u00e1va\u017en\u00e9 toxicity Stupn\u011b 3 nebo 4. Nap\u0159\u00edklad meta-anal\u00fdzy o rakovin\u011b d\u011blo\u017en\u00edho \u010d\u00edpku nezaznamenaly \u017e\u00e1dn\u00fd v\u00fdznamn\u00fd rozd\u00edl v akutn\u00ed nebo pozdn\u00ed toxicit\u011b (RR 0,99 pro akutn\u00ed toxicitu, RR 1,01 pro pozdn\u00ed toxicitu).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Toto pozorov\u00e1n\u00ed plat\u00ed i pro jin\u00e9 indikace, co\u017e posiluje argument, \u017ee HT nab\u00edz\u00ed superiorn\u00ed terapeutick\u00fd index, kter\u00fd umo\u017e\u0148uje pacient\u016fm l\u00e9pe tolerovat slo\u017eit\u00e9 l\u00e9\u010debn\u00e9 re\u017eimy a m\u00edt zlep\u0161enou Kvalitu \u017divota z dlouhodob\u00e9ho hlediska.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1v\u011br: Certifikovan\u00e1 Strategie P\u0159e\u017eit\u00ed<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A\u0165 u\u017e se jedn\u00e1 o <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">zv\u00fd\u0161en\u00ed OS o 52 % (rakovina slinivky), zv\u00fd\u0161en\u00ed o +17 procentn\u00edch bod\u016f po 12 letech (rakovina d\u011blo\u017en\u00edho \u010d\u00edpku) nebo Zdvojn\u00e1soben\u00ed doby p\u0159e\u017eit\u00ed (Glioblastom a Sarkom M\u011bkk\u00fdch Tk\u00e1\u0148),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> dokumentace z randomizovan\u00fdch studi\u00ed potvrzuje, \u017ee Hypertermie nen\u00ed pouze adjuvantn\u00ed l\u00e9\u010dba, ale kl\u00ed\u010dov\u00e1 slo\u017eka, kter\u00e1 pozitivn\u011b m\u011bn\u00ed dr\u00e1hu <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Celkov\u00e9ho P\u0159e\u017eit\u00ed<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pro onkologick\u00e9 pacienty.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pokud je va\u0161\u00edm c\u00edlem maximalizovat Celkov\u00e9 P\u0159e\u017eit\u00ed, je integrace Hypertermie do standardn\u00edho protokolu v\u011bdecky ov\u011b\u0159en\u00fdm rozhodnut\u00edm s v\u00fdsledky prokazuj\u00edc\u00edmi relativn\u00ed zv\u00fd\u0161en\u00ed o v\u00edce ne\u017e 50 % v ur\u010dit\u00fdch indikac\u00edch.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">E-E-A-T Z\u00e1ruka:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Tento obsah je zalo\u017een na konsolidovan\u00fdch datech z randomizovan\u00fdch klinick\u00fdch studi\u00ed F\u00e1ze III a prospektivn\u00edch randomizovan\u00fdch studi\u00ed, publikovan\u00fdch v presti\u017en\u00edch l\u00e9ka\u0159sk\u00fdch \u010dasopisech. Kompletn\u00ed reference jsou integrov\u00e1ny s odkazy na zdrojov\u00e9 publikace.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Reference:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorita a Odbornost (E-E-A-T): Vyvinuli Dr. Veronica Iatan , MD, a Cristian Gologan M.Sc , Andromedichyperthermia Hypertermie a P\u0159e\u017eit\u00ed u Onkologick\u00fdch Pacient\u016f: Klinick\u00e9 D\u016fkazy Ukazuj\u00ed Zv\u00fd\u0161en\u00ed Celkov\u00e9ho P\u0159e\u017eit\u00ed (OS) o V\u00edce Ne\u017e 50 % v Ur\u010dit\u00fdch P\u0159\u00edpadech V boji proti rakovin\u011b je kone\u010dn\u00fdm c\u00edlem prodlou\u017eit Celkov\u00e9 P\u0159e\u017eit\u00ed (Overall Survival, OS) s minim\u00e1ln\u00ed nebo \u017e\u00e1dnou dodate\u010dnou&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[879,29,111],"tags":[456,756,152,751,755,460,750,753,754,752,757,749,886],"class_list":["post-11293","post","type-post","status-publish","format-standard","hentry","category-studii-clinice-cs","category-uncategorized-cs","category-zpravy","tag-cr-cs","tag-glioblastom-cs","tag-hypertermie","tag-kompletni-odpoved","tag-onkologie-cs","tag-os-cs","tag-preziti","tag-rakovina-delozniho-cipku","tag-rakovina-prsu","tag-rakovina-slinivky","tag-sarkom-cs","tag-studie-faze-iii","tag-studii-faza-iii-cs"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/posts\/11293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/comments?post=11293"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/posts\/11293\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/media?parent=11293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/categories?post=11293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/cs\/wp-json\/wp\/v2\/tags?post=11293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}